{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucose-dependent+Insulinotropic+Polypeptide+%28GIP%29&page=2",
    "query": {
      "intervention": "Glucose-dependent Insulinotropic Polypeptide (GIP)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucose-dependent+Insulinotropic+Polypeptide+%28GIP%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucose-dependent+Insulinotropic+Polypeptide+%28GIP%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T21:03:50.845Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03954834",
      "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 478,
      "start_date": "2019-06-03",
      "completion_date": "2020-10-28",
      "has_results": true,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 28,
      "location_summary": "Huntington Park, California • Los Angeles, California • Montclair, California + 24 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954834"
    },
    {
      "nct_id": "NCT05375968",
      "title": "Splanchnic Venous Capacitance in Postural Tachycardia Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postural Tachycardia Syndrome (POTS)"
      ],
      "interventions": [
        {
          "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2",
          "type": "DRUG"
        },
        {
          "name": "Compare change is SVC and SMA flow due to saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-02-25",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375968"
    },
    {
      "nct_id": "NCT00239707",
      "title": "GIP: Glucose-dependent Insulinotropic Peptide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "GIP",
          "type": "DRUG"
        },
        {
          "name": "Modified GIP",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2003-02",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-28",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00239707"
    },
    {
      "nct_id": "NCT00798915",
      "title": "Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-12",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-03",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798915"
    },
    {
      "nct_id": "NCT04039503",
      "title": "A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 475,
      "start_date": "2019-08-30",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-01-12",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 5,
      "location_summary": "Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Nashua",
          "state": "New Hampshire"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Norman",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04039503"
    },
    {
      "nct_id": "NCT07793929",
      "title": "A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Renal Impairment",
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Ribupatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kailera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-09-08",
      "completion_date": "2028-02-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07793929"
    },
    {
      "nct_id": "NCT07458269",
      "title": "Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Ribupatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kailera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2026-03-04",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 35,
      "location_summary": "Mesa, Arizona • Sun City West, Arizona • Irvine, California + 31 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Lake Forest",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07458269"
    },
    {
      "nct_id": "NCT07554638",
      "title": "Incretin Therapies in Obesity-related HFpEF",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure, Diastolic",
        "Heart Failure With Preserved Ejection Fraction",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-08-07",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07554638"
    },
    {
      "nct_id": "NCT04255433",
      "title": "A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Dulaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 13299,
      "start_date": "2020-05-29",
      "completion_date": "2025-06-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Concord, California • Covina, California + 106 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04255433"
    },
    {
      "nct_id": "NCT07169851",
      "title": "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nausea",
        "Vomiting",
        "Drug-Related Side Effects and Adverse Reactions",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "LY3537021",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Antiemetic Therapies",
          "type": "DRUG"
        },
        {
          "name": "Background Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2025-11-28",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-06T21:03:50.845Z",
      "location_count": 21,
      "location_summary": "Greenbrae, California • Irvine, California • Los Alamitos, California + 18 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169851"
    }
  ]
}